Evidence map›Paper›PMID 33337368›Full record

ArticleJournal of Alzheimer's disease : JAD2021

Computational Evaluation of Interaction Between Curcumin Derivatives and Amyloid-β Monomers and Fibrils: Relevance to Alzheimer's Disease.

Adrian Orjuela, Johant Lakey-Beitia, Randy Mojica-Flores, Muralidhar L Hegde, Isaias Lans, Jorge Alí-Torres, K S Rao

Open access · greenAbstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 13 citations in OpenAlex.

  1. Specific Binding of Alzheimer's Aβ Peptides to Extracellular Vesicles.International journal of molecular sciences · 2024
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Adrian OrjuelaDepartamento de Química, Universidad Nacional de Colombia, Bogotá DC, Colombia.
Johant Lakey-BeitiaCentre for Biodiversity and Drug Discovery, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), Clayton, City of Knowledge, Panama.
Randy Mojica-FloresCentre for Biodiversity and Drug Discovery, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), Clayton, City of Knowledge, Panama.
Muralidhar L HegdeDepartment of Neurosurgery, Center for Neuroregeneration, Houston Methodist Research Institute, Houston, TX, USA.
Isaias LansBiophysics of Tropical Diseases, Max Planck Tandem Group, University of Antioquia, Medellín, Colombia.
Jorge Alí-TorresDepartamento de Química, Universidad Nacional de Colombia, Bogotá DC, Colombia.
K S RaoCentre for Neuroscience, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), Clayton, City of Knowledge, Panama.
City of Knowledge · PAUniversidad Nacional de Colombia · COCornell University · USInstituto de Investigaciones Científicas y Servicios de Alta Tecnología · PAUniversidad de Antioquia · CO

Funding

Defining the altered FUS-PARP-1-DNA Ligase III axis and its implications to nuclear and mitochondrial genome damage response in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)RF1NS112719 · NINDS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI HEGDE, MURALIDHAR L · 2020 to 2020
$2.0M
Etiological Linkage of DNA Damage/Repair Deficiency in Neurodegenerative DiseasesR01NS088645 · NINDS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI HEGDE, MURALIDHAR L · 2015 to 2019
$1.8M
A new conditional TDPΔNLS knock-in mouse model generated using CRISPR/Cas9 technology to study the linkage of TDP-43 pathology to motor and cognitive defects in ALS, FTD and ADRDR03AG064266 · NIA · METHODIST HOSPITAL RESEARCH INSTITUTE · PI HEGDE, MURALIDHAR L · 2020 to 2021
$162k
NIA NIH HHS R03 AG064266NINDS NIH HHS R01 NS088645NINDS NIH HHS RF1 NS112719
6 · The paper itself

Abstract

backgroundThe most important hallmark in the neuropathology of Alzheimer's disease (AD) is the formation of amyloid-β (Aβ) fibrils due to the misfolding/aggregation of the Aβ peptide. Preventing or reverting the aggregation process has been an active area of research. Naturally occurring products are a potential source of molecules that may be able to inhibit Aβ42 peptide aggregation. Recently, we and others reported the anti-aggregating properties of curcumin and some of its derivatives in vitro, presenting an important therapeutic avenue by enhancing these properties.

objectiveTo computationally assess the interaction between Aβ peptide and a set of curcumin derivatives previously explored in experimental assays.

methodsThe interactions of ten ligands with Aβ monomers were studied by combining molecular dynamics and molecular docking simulations. We present the in silico evaluation of the interaction between these derivatives and the Aβ42 peptide, both in the monomeric and fibril forms.

resultsThe results show that a single substitution in curcumin could significantly enhance the interaction between the derivatives and the Aβ42 monomers when compared to a double substitution. In addition, the molecular docking simulations showed that the interaction between the curcumin derivatives and the Aβ42 monomers occur in a region critical for peptide aggregation.

conclusionResults showed that a single substitution in curcumin improved the interaction of the ligands with the Aβ monomer more so than a double substitution. Our molecular docking studies thus provide important insights for further developing/validating novel curcumin-derived molecules with high therapeutic potential for AD.

Indexed as

Computer SimulationAlzheimer DiseaseAmyloidAmyloid beta-PeptidesCurcuminHumansMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingProtein Structure, SecondaryAmyloidAmyloid beta-PeptidesCurcuminAlzheimer’s diseaseAutoDock 4AutoDock VinaAβ42 fibrilAβ monomercurcumincurcumin derivativesmolecular dockingSmina

Identifiers

PMID33337368
PMCPMC8206224
OpenAlexW3111739868

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.